Details of the Drug Combination

General Information of Drug Combination (ID: DC6SBHH)

Drug Combination Name
Ceftazidime Meropenem
Indication
Disease Entry Status REF
Cystic Fibrosis Phase 4 [1]
Component Drugs Ceftazidime   DM41GRA Meropenem   DM62UHC
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Ceftazidime
Disease Entry ICD 11 Status REF
Bacteremia 1A73 Approved [2]
Bacterial infection 1A00-1C4Z Approved [3]
Endometritis N.A. Approved [2]
Meningococcal meningitis N.A. Approved [2]
Peritonitis N.A. Approved [2]
Staphylococcal pneumonia N.A. Approved [2]
Staphylococcus aureus infection N.A. Approved [2]
Pelvic inflammatory disease GA05 Investigative [2]
Ceftazidime Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Penicillin binding protein (Bact PBP) TTJP4SM NOUNIPROTAC Binder [5]
------------------------------------------------------------------------------------
Ceftazidime Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Dihydrofolate reductase (DHFR) OT3DVIGM DYR_HUMAN Decreases Activity [6]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Decreases Activity [7]
ATP-binding cassette sub-family C member 4 (ABCC4) OTO27PAL MRP4_HUMAN Increases Transport [8]
------------------------------------------------------------------------------------
Indication(s) of Meropenem
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [3]
Meningococcal meningitis N.A. Approved [4]
Peritonitis N.A. Approved [4]
Pneumococcal meningitis N.A. Approved [4]
Pseudomonas aeruginosa infectious disease N.A. Approved [4]
Meropenem Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Penicillin binding protein (Bact PBP) TTJP4SM NOUNIPROTAC Modulator [9]
------------------------------------------------------------------------------------
Meropenem Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic anion transporter 1 (SLC22A6) DTQ23VB S22A6_HUMAN Substrate [10]
------------------------------------------------------------------------------------
Meropenem Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Beta-lactamase (blaB) DEC3G7M A0A1S7IV31_ENTAS Metabolism [11]
Beta-lactamase (blaB) DENJ2SQ BLAB_BACFG Metabolism [12]
Beta-lactamase (blaB) DEBKS91 A0A1B1FBM9_ACIBA Metabolism [13]
Beta-lactamase (blaB) DECWSA9 AMPC_MORMO Metabolism [14]
Carbapenemase (cphA) DEB90AL BLAB_AERHY Metabolism [15]
New delhi metallo-beta-lactamase NDM-1 (blaNDM) DEBGCYQ A0A345N7K5_SALET Metabolism [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Meropenem Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
HLA class II histocompatibility antigen, DO beta chain (HLA-DOB) OTKADDUB DOB_HUMAN Affects Expression [17]
HLA class I histocompatibility antigen, alpha chain G (HLA-G) OTMLK1KN HLAG_HUMAN Affects Expression [17]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01044719) Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis
2 Ceftazidime FDA Label
3 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
4 Meropenem FDA Label
5 New and emerging treatment of Staphylococcus aureus infections in the hospital setting. Clin Microbiol Infect. 2008 Apr;14 Suppl 3:32-41.
6 Investigation of the effects of some drugs and phenolic compounds on human dihydrofolate reductase activity. J Biochem Mol Toxicol. 2015 Mar;29(3):135-9.
7 A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
8 Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters. Drug Metab Pharmacokinet. 2007 Feb 25;22(1):41-7.
11 FRI-4 carbapenemase-producing Enterobacter cloacae complex isolated in Tokyo, Japan. J Antimicrob Chemother. 2018 Nov 1;73(11):2969-2972.
12 Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
13 A high mortality rate associated with multidrug-resistant Acinetobacter baumannii ST79 and ST25 carrying OXA-23 in a Brazilian intensive care unit. PLoS One. 2018 Dec 28;13(12):e0209367.
14 Molecular investigation of extended-spectrum beta-lactamase genes and potential drug resistance in clinical isolates of Morganella morganii. Ann Saudi Med. 2016 May-Jun;36(3):223-8.
15 A carbapenem-resistant clinical isolate of Aeromonas hydrophila in Japan harbouring an acquired gene encoding GES-24 beta-lactamase. J Med Microbiol. 2018 Nov;67(11):1535-1537.
16 Genomic characterization of an extensively-drug resistance Salmonella enterica serotype Indiana strain harboring bla NDM-1 gene isolated from a chicken carcass in China. Microbiol Res. 2017 Nov;204:48-54.
17 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.